Related Experiment Video

Updated: Aug 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Mechanisms for antiplatelet action of statins

Luca Puccetti1, Anna Laura Pasqui, Alberto Auteri

  • 1Department of Clinical Medicine and Immunological Sciences, Internal Medicine Division, Policlinico Le Scotte, University of Siena, V.le Bracci, 53100, Siena, Italy. puccetti@unisi.it

Current Drug Targets. Cardiovascular & Haematological Disorders
|April 28, 2005
PubMed

Insights

Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) offer cardiovascular benefits beyond cholesterol reduction. This review explores their antiplatelet effects, crucial for preventing atherothrombosis.

Area of Science:

  • Cardiovascular Pharmacology
  • Hematology
  • Biochemistry

Background:

  • Hydroxymethyl-glutaryl coenzyme A reductase inhibitors (statins) are widely used for cardiovascular disease prevention.
  • Clinical benefits of statins may exceed those predicted by lipid-lowering effects alone.
  • Platelet hyperactivity is implicated in atherothrombosis, suggesting a potential antiplatelet role for statins.

Purpose of the Study:

  • To review human studies on the effects of statins on platelet function.
  • To explore the mechanisms underlying statin-induced platelet deactivation.
  • To differentiate between lipid-lowering dependent and independent effects of statins on platelets.

Main Methods:

  • Review of clinical studies investigating statin effects on platelets.
  • Utilized sensitive methods like cytofluorimetry for platelet protein detection.
  • Analysis of proposed mechanisms for statin-mediated platelet inhibition.

Main Results:

  • Evidence suggests statins exert antiplatelet effects, contributing to their atheroprotective action.
  • Studies show variations among statin compounds regarding the timing and pathways of action.
  • Potential for early, cholesterol-independent effects in acute vascular events and chronic treatment benefits.

Conclusions:

  • Statins possess antiplatelet properties that contribute to their cardiovascular benefits.
  • Mechanisms include both lipid-dependent and independent pathways.
  • Understanding these effects can optimize statin therapy for vascular disease prevention.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...